A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients

BACKGROUND: This study aimed to evaluate the efficacy and safety of mecapegfilgrastim (HHPG-19K) with different doses compared to granulocyte colony-stimulating growth factor (G-CSF) in treating chemotherapy-induced neutropenia in breast cancer patients. METHODS: A total of 182 breast cancer patient...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Transl Med
Hlavní autoři: Wang, Tao, Wu, Biao, Hu, Xichun, Liu, Jinping, Zhang, Tao, Li, Funian, Sun, Bing, Cai, Li, Li, Xinzheng, Chen, Zhiyue, Yang, Qing, Jiang, Zefei
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6545320/
https://ncbi.nlm.nih.gov/pubmed/31205914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.04.10
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky